


PHARMACEUTICAL 2020

Kura Oncology Inc. Rank 86 of 362





PHARMACEUTICAL 2020



Kura Oncology Inc. Rank 86 of 362

The relative strengths and weaknesses of Kura Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 325% points. The greatest weakness of Kura Oncology Inc. is the variable Revenues, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is -11%, being 292% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	239,603
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,564
Liabilities, Non-Current	7,627
Other Assets	2,325
Other Compr. Net Income	462
Other Expenses	0
Other Liabilities	0
Other Net Income	4,339
Property and Equipment	44
Research and Development	47,826
Revenues	0
Selling, General and Administrative Expense	19,653

Output Variable	Value in 1000 USD
Assets	241,972
Liabilities	23,191
Expenses	67,479
Stockholders Equity	218,781
Net Income	-63,140
Comprehensive Net Income	-62,909
Economic Capital Ratio	-11%